lobbying_activities: 1074187

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1074187	59272260-6c00-4742-beca-51fda4dcd01d	Q1	MEHLMAN CONSULTING, INC.	284950	ASTRAZENECA PHARMACEUTICALS	2011	first_quarter	MMM	Discussions and possible legislation regarding possible increase in Medicaid program base rebate rate issues arising from Deficit Reduction Act. Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage. Legislation to address physician payments issues, including SGR and related provisions to Medicare package.	HOUSE OF REPRESENTATIVES,SENATE	50000		0	0	2011-04-13T10:12:55.767000-04:00